Ocugen signs exclusive OCU400 MENA license with Roots Pharmaceutical

Ocugen signed an exclusive license agreement with Roots Pharmaceutical for OCU400 in the MENA region. The deal is eligible for up to $4M upfront and milestones, up to $255M in sales milestones, and a 22% royalty.

Detected & updated continuously · Source: Nebula